Jul. 22 at 1:48 PM
$INSM TD Cowen
Ritu Baral Reaffirms Buy on Insmed, Raising Price Target from
$200 to
$243 Ahead of Q2 Preview
Ritu Baral has given her Buy rating due to a combination of factors, including her updated modeling and estimates for Insmed ahead of the Q2 industry preview. Her positive stance reflects confidence in Insmed’s underlying business fundamentals and the company’s strategic trajectory, which she believes can support continued value creation for shareholders.
She also raised her official price target from
$200 to
$243, signaling increased conviction in the stock’s upside potential based on revised assumptions and sector insights discussed in the broader Q2 preview. This higher target suggests that, in her view, Insmed’s risk‑reward profile remains attractive, justifying the Buy recommendation.
